(-)-Epinephrine (+)-bitartrate: Adrenergic Receptor Agonist for Cardiovascular and Neurobiology Research

Executive Summary: (-)-Epinephrine (+)-bitartrate (L-Epinephrine Bitartrate) is a non-selective adrenergic receptor agonist targeting α₁/α₂ and β₁/β₂/β₃ receptors, modulating vasoconstriction, heart rate, and bronchodilation with EC₅₀ values of 10 nM (β₁), 5 nM (α₁), and 8 nM (β₂) [APExBIO Product]. It is highly soluble in DMSO (≥16.66 mg/mL) and water (≥22.9 mg/mL), but insoluble in ethanol, supporting flexible application in vitro and in vivo. In laboratory research, it is used at 1 nM–10 μM concentrations for cell assays, and is a reference standard for adrenergic receptor activation (Liu et al., 2019). Clinical applications include anaphylactic shock and acute asthma therapy. Misapplication may cause arrhythmias or hypertension, and it is contraindicated in pheochromocytoma and hyperthyroidism.

Biological Rationale

(-)-Epinephrine (+)-bitartrate is the bitartrate salt of epinephrine, also known as adrenaline, a principal catecholamine neurotransmitter and hormone. It is central to the sympathetic nervous system's fight-or-flight response, mediating rapid physiological adjustments. This compound's non-selective agonism of adrenergic receptors enables modulation of cardiovascular, respiratory, and metabolic systems. Its robust, predictable action profile makes it a valuable research tool for mapping adrenergic signaling pathways and evaluating cardiovascular and neurobiological functions [see Advanced Insights]. Compared to norepinephrine or selective agonists, (-)-Epinephrine (+)-bitartrate provides a broader activation spectrum, critical for dissecting receptor subtype contributions.

Mechanism of Action of (-)-Epinephrine (+)-bitartrate

(-)-Epinephrine (+)-bitartrate binds and activates both α (α₁, α₂) and β (β₁, β₂, β₃) adrenergic receptors. Binding triggers conformational changes, initiating G protein-coupled receptor (GPCR) signaling cascades. α₁-receptor activation induces vasoconstriction via Gq/11 and phospholipase C. β₁-receptor activation increases cardiac contractility and heart rate through Gs and cAMP pathways. β₂-receptors mediate bronchodilation and vascular smooth muscle relaxation, also via cAMP. The compound's EC₅₀ values—10 nM (β₁), 5 nM (α₁), and 8 nM (β₂)—reflect its high potency and broad receptor engagement [APExBIO]. The bitartrate counterion improves aqueous solubility and stability, facilitating in vitro and in vivo use.

Evidence & Benchmarks

• (-)-Epinephrine (+)-bitartrate demonstrates nanomolar affinity for β₂-adrenergic receptors, with binding constants (Kb) in accordance with other reference adrenergic agonists (Liu et al., 2019, DOI).
• Solubility is ≥16.66 mg/mL in DMSO and ≥22.9 mg/mL in water, but the compound is insoluble in ethanol (APExBIO Product, link).
• Standard in vitro concentrations range from 1 nM to 10 μM for cell signaling assays; in vivo dosages are species- and route-dependent (e.g., 0.15–0.3 mg IM, 2–20 mg intranasally in canines) (APExBIO).
• It is employed clinically for emergency management of anaphylactic shock and acute bronchial asthma exacerbations, and as a vasoconstrictor adjunct to local anesthesia (APExBIO).
• Binding constant determination using open-tubular capillary electrochromatography is reliable and aligns with computational predictions (Liu et al., 2019, DOI).

This article extends the workflow-focused guide at adrenorphin.net by adding quantitative solubility, EC₅₀, and binding data benchmarks for experimental reproducibility.

Applications, Limits & Misconceptions

Core applications:

• Cardiovascular disease research: Use as a tool for modeling adrenergic responses in heart and vessel tissues (mek12.com).
• Sympathetic nervous system research: Mapping acute stress, fight-or-flight mechanisms, and neurobiology studies.
• Cell signaling assays: Benchmark for β-adrenergic receptor activation and downstream cAMP/PKA pathway interrogation.
• Emergency medicine: Reference for anaphylactic shock treatment and acute asthma therapy (clinical, not for research-only grades).
• Adjunct to local anesthetics: Prolongs anesthetic effect and reduces surgical bleeding.

This article clarifies the molecular and benchmarking detail compared to the scenario-driven troubleshooting at sb-715992.com, emphasizing quantitative parameters for cell signaling assays.

Common Pitfalls or Misconceptions

• Not all adrenergic effects are mediated equally—receptor subtype expression varies by tissue and species.
• Overdose can cause cardiac arrhythmias, severe hypertension, and is contraindicated in pheochromocytoma or hyperthyroidism (APExBIO).
• Long-term storage of solutions is discouraged due to degradation—prepare fresh aliquots for experiments.
• Solubility is poor in ethanol; do not attempt to dissolve in alcohol-based media.
• Clinical-grade product is required for therapeutic use; APExBIO B1358 is research-use only.

Workflow Integration & Parameters

Preparation and storage:

• Dissolve at ≥16.66 mg/mL in DMSO or ≥22.9 mg/mL in water; filter sterilize if needed.
• Store dry powder at -20°C. Avoid repeated freeze-thaw cycles of solutions.

Assay setup:

• For in vitro cell signaling assays, use 1 nM–10 μM depending on endpoint sensitivity and receptor expression.
• For cardiovascular or neurobiology models, titrate dose based on species, route, and desired physiological response (adrenorphin.net).
• Benchmark with matched negative controls and, where possible, receptor antagonists to confirm specificity.

This article updates the mechanistic angle reviewed at adrenorphin.net by providing actionable solubility, dosing, and storage parameters for reproducible protocol design.

Conclusion & Outlook

(-)-Epinephrine (+)-bitartrate remains a gold-standard non-selective adrenergic receptor agonist for research in cardiovascular disease, neurobiology, and sympathetic nervous system pathways. Its robust solubility, nanomolar potency, and well-documented mechanisms support reproducibility and translational insights. Future research may further dissect subtype-selective analogs, but the reference activity of (-)-Epinephrine (+)-bitartrate (as supplied by APExBIO) remains foundational for benchmarking new models and interventions.